Identification of natural killer markers associated with fatal outcome in COVID-19 patients

Front Cell Infect Microbiol. 2023 Jun 5:13:1165756. doi: 10.3389/fcimb.2023.1165756. eCollection 2023.

Abstract

Introduction: Increasing evidence has shown that coronavirus disease 19 (COVID-19) severity is driven by a dysregulated immunological response. Previous studies have demonstrated that natural killer (NK) cell dysfunction underpins severe illness in COVID-19 patients, but have lacked an in-depth analysis of NK cell markers as a driver of death in the most critically ill patients.

Methods: We enrolled 50 non-vaccinated hospitalized patients infected with the initial virus or the alpha variant of SARS-CoV-2 with moderate or severe illness, to evaluate phenotypic and functional features of NK cells.

Results: Here, we show that, consistent with previous studies, evolution NK cells from COVID-19 patients are more activated, with the decreased activation of natural cytotoxicity receptors and impaired cytotoxicity and IFN-γ production, in association with disease regardless of the SARS-CoV-2 strain. Fatality was observed in 6 of 17 patients with severe disease; NK cells from all of these patients displayed a peculiar phenotype of an activated memory-like phenotype associated with massive TNF-α production.

Discussion: These data suggest that fatal COVID-19 infection is driven by an uncoordinated inflammatory response in part mediated by a specific subset of activated NK cells.

Keywords: COVID-19; SARS-CoV-2 infection; fatal outcome; natural killer (Nk) cell; tNF-alpha.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • COVID-19 Vaccines
  • COVID-19* / immunology
  • COVID-19* / pathology
  • COVID-19* / physiopathology
  • Fatal Outcome
  • Humans
  • Killer Cells, Natural* / immunology
  • Killer Cells, Natural* / metabolism
  • Killer Cells, Natural* / pathology
  • Lymphocyte Activation
  • Male
  • Middle Aged
  • Patient Acuity
  • Receptors, Natural Killer Cell / metabolism
  • SARS-CoV-2* / classification
  • SARS-CoV-2* / physiology
  • Tumor Necrosis Factor-alpha

Substances

  • COVID-19 Vaccines
  • Receptors, Natural Killer Cell
  • Tumor Necrosis Factor-alpha

Grants and funding

This work was funded by the ANR Flash COVID19 program and Sorbonne by the SARS-CoV-2 Program of the Faculty of Medicine from Sorbonne University (ICOViD programs) for financial support.